Coinbase CEO's Longevity Startup NewLimit Raises $435 Million at $3.1 Billion Valuation

NewLimit, the cell-reprogramming startup co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C led by Founders Fund, tripling its valuation.

Coinbase CEO's Longevity Startup NewLimit Raises $435 Million at $3.1 Billion Valuation NewLimit, the cell-reprogramming startup co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C led by Founders Fund, tripling its valuation. Aaron Rafferty June 23, 2026 Key Takeaways NewLimit, the longevity startup co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C led by Founders Fund, announced June 2, roughly tripling its valuation to about $3.1 billion. The company uses epigenetic reprogramming to reset aging cells, and it plans its first human trial, targeting liver disease, in 2027. The round extends a pattern of crypto-built fortunes moving into frontier science, echoing Tether's recent lead of a $1.4 billion robotics round. NewLimit, the longevity biotech co-founded by Coinbase CEO Brian Armstrong, raised a 435 million dollar Series C led by Founders Fund, the company announced June 2 , according to STAT News. The round roughly tripled its valuation to about 3.1 billion dollars, up from a mark that sat below 1 billion dollars a year earlier. Founded in 2021 by Armstrong, bioengineer Blake Byers, and stem cell biologist Jacob Kimmel, NewLimit works on epigenetic reprogramming, which resets the chemical markers that tell genes when to switch on without changing the underlying DNA, as Bitcoin.com News reported . The goal is to make old cells behave like young ones, and Armstrong has put about 110 million dollars of his own money into the company. The capital moves NewLimit toward the clinic. The company said a prototype reversed the age of old human liver cells, and it plans to begin its first human trial, targeting liver disease, in 2027, per CryptoNews . It remains pre-revenue with no approved product, and its backers now i